Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameDocosanol
Accession NumberDB00632  (APRD00933)
Typesmall molecule
Groupsapproved, investigational
Description

Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.

Structure
Thumb
Synonyms
SynonymLanguageCode
Behenic alcoholNot AvailableIS
Behenyl alcoholNot AvailableINCI
Docosan-1-olNot AvailableIS
DocosanolFrench/GermanINN
Docosyl alcoholNot AvailableIS
SaltsNot Available
Brand names
NameCompany
AbrevaGlaxoSmithKline
BlistexDDD
ErazabanHealthcare
HealipAco Hud
LafrostIncepta
Brand mixturesNot Available
Categories
CAS number30303-65-2
WeightAverage: 326.6
Monoisotopic: 326.354866094
Chemical FormulaC22H46O
InChI KeyInChIKey=NOPFSRXAKWQILS-UHFFFAOYSA-N
InChI
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
IUPAC Name
docosan-1-ol
SMILES
CCCCCCCCCCCCCCCCCCCCCCO
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassFatty Alcohols
SubclassNot Available
Direct parentFatty Alcohols
Alternative parentsPrimary Alcohols; Polyamines
Substituentspolyamine; primary alcohol; alcohol
Classification descriptionThis compound belongs to the fatty alcohols. These are aliphatic alcohols consisting of a chain of 8 to 22 carbon atoms.
Pharmacology
IndicationFor the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
PharmacodynamicsDocosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol cannot, however, prevent cold sores or fever blisters from appearing.
Mechanism of actionDocosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV.
AbsorptionTopical absorption has been shown to be minimal under conditions reflecting normal clinical use.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia.
Affected organisms
  • Herpes simplex virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9947
Blood Brain Barrier + 0.9579
Caco-2 permeable + 0.7688
P-glycoprotein substrate Non-substrate 0.618
P-glycoprotein inhibitor I Non-inhibitor 0.9201
P-glycoprotein inhibitor II Non-inhibitor 0.9092
Renal organic cation transporter Non-inhibitor 0.8735
CYP450 2C9 substrate Non-substrate 0.7931
CYP450 2D6 substrate Non-substrate 0.8437
CYP450 3A4 substrate Non-substrate 0.7094
CYP450 1A2 substrate Non-inhibitor 0.5
CYP450 2C9 substrate Non-inhibitor 0.8798
CYP450 2D6 substrate Non-inhibitor 0.9262
CYP450 2C19 substrate Non-inhibitor 0.933
CYP450 3A4 substrate Non-inhibitor 0.9142
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8928
Ames test Non AMES toxic 0.9872
Carcinogenicity Non-carcinogens 0.5579
Biodegradation Ready biodegradable 0.8849
Rat acute toxicity 1.5561 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.8578
hERG inhibition (predictor II) Non-inhibitor 0.7525
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
CreamTopical
Prices
Unit descriptionCostUnit
Abreva 10% cream7.57USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States48747941994-04-282014-04-28
United States55345541993-12-132013-12-13
Canada24210262005-02-152022-10-15
Canada21560631999-06-292019-06-29
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point65-72 °CNot Available
logP9Not Available
Predicted Properties
PropertyValueSource
water solubility1.96e-05 g/lALOGPS
logP9.31ALOGPS
logP8.81ChemAxon
logS-7.2ALOGPS
pKa (strongest acidic)16.84ChemAxon
pKa (strongest basic)-2ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count1ChemAxon
hydrogen donor count1ChemAxon
polar surface area20.23ChemAxon
rotatable bond count20ChemAxon
refractivity104.95ChemAxon
polarizability47.27ChemAxon
number of rings0ChemAxon
bioavailability0ChemAxon
rule of fiveNoChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
Spectra
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ResourceLink
PubChem Compound12620
PubChem Substance46508049
ChemSpider12100
ChEBI31000
ChEMBLCHEMBL1200453
Therapeutic Targets DatabaseDAP001249
PharmGKBPA164749211
Drug Product Database2245677
Drugs.comhttp://www.drugs.com/cdi/docosanol.html
WikipediaDocosanol
ATC CodesD06BB11
AHFS Codes
  • 84:04.06
PDB EntriesNot Available
FDA labelshow(622 KB)
MSDSshow(59.7 KB)
Interactions
Drug InteractionsSearched, but no interactions found.
Food InteractionsNot Available

1. Envelope glycoprotein GP350

Kind: protein

Organism: HHV-4

Pharmacological action: yes

Actions: intercalation

Components

Name UniProt ID Details
Envelope glycoprotein GP350 P03200 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Treister NS, Woo SB: Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother. 2010 Apr;11(5):853-60. Pubmed
  4. Leung DT, Sacks SL: Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004 Dec;5(12):2567-71. Pubmed
  5. Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML, Spear PG: The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res. 1998 Dec;40(1-2):85-94. Pubmed

2. Envelope glycoprotein GP340

Kind: protein

Organism: HHV-4

Pharmacological action: unknown

Actions: intercalation

Components

Name UniProt ID Details
Envelope glycoprotein GP340 P68344 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Leung DT, Sacks SL: Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004 Dec;5(12):2567-71. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11